Patheon Acquires IRIX Pharmaceuticals

Article

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

 

Patheon announced on March 4 that it has reached a definitive agreement to acquire Florence, SC-based IRIX Pharmaceuticals, which specializes in difficult-to-manufacture APIs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in 60 days.

Patheon reports that with the acquisition, it secures additional API development and manufacturing services in the United States, including high-potency (SafeBridge Class IV-certified) and controlled substances (Schedule 1-4). IRIX has facilities for the optimization of chemical processes and scale up for commercial API manufacturing in Florence and Greenville, SC.

The combined companies will offer an array of process technologies, including biocatalysis, homogeneous catalysis, and microreactors and are positioned to address a range of supply chain issues for customers, according to a press statement.

Source: Patheon

Recent Videos
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content